-

C-C Chemokine Receptor Type 8 (CCR8) Targeted Antibody Immunotherapy Pipeline Review 2024 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "CCR8-Targeted Antibody Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering.

CCR8 is an emerging, highly attractive next generation immuno-oncology target which has attracted great interest among small and large biopharmaceutical companies. The field is not yet overcrowded and, therefore, ideally suited for antibody technology companies as well as for development companies in the immune-oncology field.

CCR8 is a type of chemokine receptor that belongs to the C-C subfamily and is a G protein-coupled receptor (GPCR) with seven transmembrane domains. This receptor is mainly expressed in monocytes, Th2 cells, and Treg cells, and it plays a critical role in the development of autoimmune diseases and tumors. The primary ligand for CCR8 in humans is CCL1, which binds to the extracellular loop 2 (ECL2) and the N-terminal domain of the receptor.

CCR8 is a GPCR with prevalent and highly specific expression on immunosuppressive tumor infiltrating regulatory T cells (Tregs) across different tumor types. Stimulation of CCR8 by its ligand results in proliferation of Tregs in the tumor microenvironment and immune-suppression. CCR8 is upregulated in tumor tissues, including head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). CCR8 is highly expressed in tumor-infiltrating Tregs and correlates with poor prognosis in both NSCLC and CRC patients.

Targeting CCR8 with an antibody able to mediate cell killing through antibody-dependent cellular cytotoxicity (ADCC) offers the potential to selectively deplete highly immunosuppressive Tregs in the tumor microenvironment and promote anti-tumor immunity. This target can potentially serve as a treatment for a broad range of cancers, alone and in combination with checkpoint inhibitors.

For more information about this report visit https://www.researchandmarkets.com/r/ffr51k

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

UAE Colocation Data Center Portfolio Analysis Report 2025: Khazna Data Centers, Pure Data Centers and Gulf Data Hub Rank Among the Leading Data Center Operators by Capacity - Forecast to 2029 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "UAE Existing & Upcoming Data Center Portfolio" database has been added to ResearchAndMarkets.com's offering. The United Arab Emirates dominates the existing market with a power capacity of more than 400 MW, driven by major players like Khazna Data Centers, Equinix, and Gulf Data Hub. Dubai dominates the upcoming data center market, accounting for nearly 80% of the planned capacity. Khazna Data Center leads the market with multiple large-scale projects in Dubai,...

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Rigel Pharmaceuticals Leads With Fostamatinib and Hutchmed's Sovleplenib Emerges as Late-Stage Breakthrough Candidate for ITP - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2030" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Global SYK Inhibitor Market Growth 2020-2024: 13% CAGR Approved SYK Inhibitor Drugs: 1 Dosage, Price & Sales Insight of Approved Drug Global Market Trend, Size & Future Opportunity Outlook Comprehensive Insight on Global SYK Inhibitors Clinical Pipeline: > 15 Drugs Global SYK Inhibitors...

Brazil Colocation Data Center Portfolio Report/Database 2025-2029: Detailed Analysis of 83 Existing Data Centers, 34 Upcoming Data Centers, and 37 Major Operators/Investors - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Brazil Existing & Upcoming Data Center Portfolio" database has been added to ResearchAndMarkets.com's offering. Brazil's data center landscape is entering a high-growth phase, with upcoming IT load capacity projected to exceed current operational capacity by more than 2.5 times, underscoring strong market expansion and hyperscale demand. Over 34+ upcoming colocation and hyperscale self-built data center projects in Brazil are expected to add over 2.8 GW of capa...
Back to Newsroom